Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
Open Access
- 11 August 2023
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (10) , 4504-4522
Abstract
Introduction Biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are important treatments for rheumatoid arthritis (RA). As more of these drugs become available, there is a greater need to assess their real-world adherence and drug survival. Methods Treatment-naïve and treatment-experienced patients with RA who initiated treatment with bDMARDs and tofactinib during 2015–2018 in a large Israeli health maintenance organization were included. Adherence and time to treatment suspension were recorded. Odds for adherence were estimated using a multivariable logistic regression model. Risk for treatment suspension was estimated using a mixed-effect Cox proportional hazard model. Results The analysis included 753 eligible patients (61.8% treatment-naïve) treated with 1287 treatment episodes (tofacitinib 24.2%, tocilizumab 17.5%, etanercept 16.0%, adalimumab 10.4%, abatacept 9.9%, rituximab 9.0%, golimumab 6.9%, certolizumab pegol 3.6%, infliximab 1.9%, and sarilumab 0.5%). Good adherence was measured for almost all drugs, yet over 50% of all treatment episodes were suspended. Older age was associated with reduced risk for treatment suspension while higher number of primary care visits and higher Charlson’s comorbidity score were associated with increased risk. Compared to etanercept, treatment with adalimumab, certolizumab, or rituximab was associated with increased risk for treatment suspension (HR 1.68 95% CI 1.27–2.22, HR 1.62 95% CI 1.00–2.60, and HR 2.72 95% CI 2.02–3.67, respectively). Conclusion Treatment choice primarily depends on disease activity and prognosis. Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy.Keywords
Funding Information
- AbbVie
This publication has 52 references indexed in Scilit:
- Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patientsArthritis Research & Therapy, 2014
- Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?Arthritis & Rheumatology, 2013
- Adherence to biologic DMARD therapies in rheumatoid arthritisExpert Opinion on Biological Therapy, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2010
- Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic DrugsThe Journal of Rheumatology, 2009
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- How can we improve adherence to therapy by patients with rheumatoid arthritis?Nature Clinical Practice Rheumatology, 2007
- A Checklist for Medication Compliance and Persistence Studies Using Retrospective DatabasesValue in Health, 2007
- Methods for evaluation of medication adherence and persistence using automated databasesPharmacoepidemiology and Drug Safety, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987